Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats
Authors:
- Moisés García-ArencibiaMGMoisés García-Arencibia
- Luca FerraroLuca Ferraro
- Sergio TanganelliSTSergio Tanganelli
- Javier Fernández-RuizJFJavier Fernández-Ruiz
- 1 June 2008
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 438 (1) , 10-13
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's diseaseBrain Research, 2006
- Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonismNeurobiology of Disease, 2005
- Cannabinoid Control of Motor Function at the Basal Ganglia2005
- Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's modelNeurobiology of Disease, 2004
- CB cannabinoid receptor signalling in Parkinson’s diseaseCurrent Opinion in Pharmacology, 2003
- Experimental Parkinsonism Alters Endocannabinoid Degradation: Implications for Striatal Glutamatergic TransmissionJournal of Neuroscience, 2002
- Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosetsEuropean Journal of Neuroscience, 2001
- The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro StudyCerebral Cortex, 2001
- Functional changes of the basal ganglia circuitry in Parkinson's diseaseProgress in Neurobiology, 2000
- Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's diseaseThe FASEB Journal, 2000